Methods |
For characteristics see Anderson 2014a1
|
Participants |
|
Interventions |
|
Outcomes |
|
Notes |
|
Risk of bias |
Bias |
Authors' judgement |
Support for judgement |
Random sequence generation (selection bias) |
Unclear risk |
Not described |
Allocation concealment (selection bias) |
Unclear risk |
Not described |
Blinding of participants and personnel (performance bias) All outcomes |
Unclear risk |
Investigators and participants were blinded to the study drug treatment regimen, but it was not stated how the blinding was maintained. |
Blinding of outcome assessment (detection bias) All outcomes |
Unclear risk |
Not described |
Incomplete outcome data (attrition bias) All outcomes |
Unclear risk |
More than 5% of participants did not complete the study (19%), according to study protocol |
Selective reporting (reporting bias) |
Low risk |
A protocol was found (NCT01074008) |
Vested‐interest bias |
High risk |
This study was funded by AbbVie |
Other bias |
Low risk |
The trial appeared to be free of other components that could put it at risk of bias |